Ausdal Financial Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ausdal Financial Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$270K	Sell	1,706 -96	-5%	-$13K	0.01%	864
2026 Q1	$230K	Sell	1,802 -120	-6%	-$15K	0.01%	884
2025 Q4	$234K	Buy	+1,922	New	+$220K	0.01%	834
2023 Q2	–	Sell	-13,590	Closed	-$1.04M	–	471
2023 Q1	$1.04M	Sell	13,590 -54	-0.4%	-$4.48K	0.14%	161
2022 Q4	$1.13M	Buy	13,644 +49	+0.4%	+$3.97K	0.16%	147
2022 Q3	$1.08M	Sell	13,595 -2,169	-14%	-$183K	0.17%	146
2022 Q2	$1.17M	Buy	15,764 +2,160	+16%	+$162K	0.18%	154
2022 Q1	$1.22M	Buy	13,604 +5,630	+71%	+$520K	0.17%	159
2021 Q4	$893K	Buy	7,974 +11	+0.1%	+$1.33K	0.12%	196
2021 Q3	$1M	Hold	7,963	–	–	0.15%	173
2021 Q2	$1.08M	Hold	7,963	–	–	0.16%	166
2021 Q1	$1.08M	Buy	7,963 +16	+0.2%	+$2.4K	0.18%	150
2020 Q4	$1.12M	Buy	7,947 +29	+0.4%	+$3.71K	0.22%	134
2020 Q3	$882K	Sell	7,918 -65	-0.8%	-$7.29K	0.21%	128
2020 Q2	$894K	Buy	7,983 +13	+0.2%	+$1.28K	0.3%	96
2020 Q1	$757K	Buy	7,970 +1,179	+17%	+$104K	0.27%	99
2019 Q4	$622K	Buy	6,791 +774	+13%	+$67K	0.18%	138
2019 Q3	$459K	Sell	6,017 -76	-1%	-$6.32K	0.16%	167
2019 Q2	$529K	Sell	6,093 -1,508	-20%	-$129K	0.2%	135
2019 Q1	$688K	Buy	+7,601	New	+$647K	0.28%	92
2018 Q4	–	Sell	-3,816	Closed	-$366K	–	408
2018 Q3	$366K	Sell	3,816 -316	-8%	-$30.6K	0.1%	238
2018 Q2	$393K	Buy	4,132 +509	+14%	+$46.8K	0.12%	227
2018 Q1	$318K	Sell	3,623 -220	-6%	-$20.1K	0.11%	237
2017 Q4	$326K	Buy	+3,843	New	+$322K	0.12%	236
2016 Q3	–	Sell	-4,903	Closed	-$265K	–	280
2016 Q2	$265K	Buy	+4,903	New	+$269K	0.14%	182
2016 Q1	–	Sell	-36	Closed	-$3K	–	1034
2015 Q4	$3K	Buy	+36	New	+$2.46K	﹤0.01%	1185

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Ausdal Financial Partners's XBI Position: Q2 2026 in Review

Ausdal Financial Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 5.3% in Q2 2026, selling an estimated $13K and leaving 1,706 shares worth $270K. The position accounts for 0.01% of the portfolio, ranked #864.

Ausdal Financial Partners first reported a position in XBI in Q4 2015 and has held it in 26 quarters since. The position peaked at $1.22M in Q1 2022. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Ausdal Financial Partners held 1,706 shares of State Street SPDR S&P Biotech ETF worth $270K as of Q2 2026.
Ausdal Financial Partners sold 96 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $13K.
State Street SPDR S&P Biotech ETF made up 0.01% of Ausdal Financial Partners's portfolio in Q2 2026, its #864 holding.
Ausdal Financial Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2015 and has held it in 26 quarters since.
Ausdal Financial Partners's State Street SPDR S&P Biotech ETF position peaked at $1.22M in Q1 2022.
934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Ausdal Financial Partners's 13F filing for Q2 2026, filed 14 Aug 2026.